Neumora Therapeutics (NMRA) Other Non-Current Liabilities (2022 - 2024)
Neumora Therapeutics' quarterly Other Non-Current Liabilities came in at $22000.0 in Q4 2024, down 85.81% year-on-year from $155000.0 in Q1 2024, and down 60.0% quarter-over-quarter from $55000.0 in Q3 2024.
Neumora Therapeutics has reported Other Non-Current Liabilities for 3 years, with the latest figure at $22000.0 in Q4 2024.
- For the quarter ending Q4 2024, Other Non-Current Liabilities fell 85.81% year-over-year to $22000.0; the trailing twelve-month figure through Dec 2024 stood at $22000.0 (down 85.81% YoY), and the FY2024 full-year result was $22000.0, down 85.81% from the prior year.
- Other Non-Current Liabilities for Q4 2024 stood at $22000.0, down from $55000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $628000.0 in Q4 2022, with the low at $22000.0 in Q4 2024.
- Average Other Non-Current Liabilities over 3 years is $179857.1, with a median of $122000.0 recorded in 2024.
- Peak annual rise in Other Non-Current Liabilities reached 70.74% in 2024, while the deepest fall reached 85.81% in 2024.
- Tracing NMRA's Other Non-Current Liabilities over 3 years: stood at $628000.0 in 2022, then tumbled by 75.32% to $155000.0 in 2023, then plunged by 85.81% to $22000.0 in 2024.
- The last three Other Non-Current Liabilities figures came in at $22000.0 (Q4 2024), $55000.0 (Q3 2024), and $89000.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 55,000.00 |
| Jun 30, 2024 | 89,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | 155,000.00 |
| Sep 30, 2023 | 188,000.00 |
| Dec 31, 2022 | 628,000.00 |